XtalPi (HKG:2228) said its wholly owned subsidiary, LCC Technologies, has entered into a drug discovery collaboration with Stanford University, according to a Thursday filing with the Hong Kong bourse.
The collaboration will combine Stanford's disease biology research with LCC Technologies' automated and AI-driven small-molecule discovery platform to develop potential new therapies.
Shares of the firm were up nearly 9% in Friday morning trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.